S&P 500 Healthcare Sector SEC Filings — March 02, 2026

02-03-2026

NewAmsterdam Pharma released an investor presentation highlighting obicetrapib's clinical progress, including topline results from BROOKLYN, BROADWAY, and TANDEM Phase 3 trials showing 35-40% LDL-C lowering as monotherapy and 45% Lp(a) lowering, with an observed MACE reduction at 1-year and cash position of ~$729M at YE2025 supporting potential US launch if approved. The presentation emphasizes a $8B+ global peak sales opportunity targeting ~30M US patients not at LDL-C goals, beneficial effects beyond LDL-C on ApoB, HDL-C, Lp(a), and other markers, alongside comprehensive IP until mid-2043. Company doubled workforce to ~100 employees while building commercial functions, though forward-looking statements note risks like trial uncertainties and market access hurdles.

• ·~75M US patients with elevated Lp(a) >100-125 nmol/L, ~18M US patients far from LDL-C goal (>20% above), ~5M ASCVD patients not at LDL-C <70 mg/dL, ~8M high-risk ASCVD not at <55 mg/dL
• ·Non-statin LLT growth in high double digits, Repatha +45% Rx growth in 2024
• ·IP protection until mid-2043, blinded data in >9,500 patients

02-03-2026

Core Scientific reported Q4 2025 total revenue of $79.8 million, down 16% YoY from $94.9 million, primarily due to a 47% decline in digital asset self-mining revenue to $42.2 million despite a 268% surge in colocation revenue to $31.3 million and a slight 4% drop in hosted mining revenue to $6.3 million. Gross profit rose sharply 336% to $20.8 million and net income flipped to $216.0 million from a $291.1 million loss, driven by non-cash gains; however, Adjusted EBITDA swung to -$42.7 million from $13.3 million amid higher digital asset fair value changes. The company expanded power capacity by ~730 MW across new and existing sites and disclosed a material restatement of prior-period financials for overstated property, plant, and equipment with no impact on revenue, Adjusted EBITDA, or cash flows.

• ·Liquidity of $533.4M as of Dec 31, 2025, comprising $311.4M cash and $222.0M bitcoin.
• ·Restatement impacts consolidated financials as of/for: three/six months ended June 30, 2024; nine months ended Sep 30, 2024; year ended Dec 31, 2024; three months ended Mar 31, 2025; six months ended June 30, 2025; three months ended Sep 30, 2025 (standalone June 30/Sep 30 2024/2025 unaffected).
• ·Conference call scheduled for March 2, 2026 at 4:30 pm ET; investor presentation available at https://investors.corescientific.com/news-events/presentations.

02-03-2026

On February 24, 2026, Pacific Oak Strategic Opportunity REIT, Inc. dismissed Ernst & Young, LLP as its independent auditor effective immediately, with no disagreements or reportable events noted over the prior two fiscal years. The Board dissolved the audit committee, ceased plans to file Annual Reports on Form 10-K or Quarterly Reports on Form 10-Q, and opted instead for Current Reports on Form 8-K including quarterly IFRS financial statements of its BVI subsidiary, while deciding against seeking stockholder approval for a liquidation plan amid limited cash and uncertain funding. These actions coincide with ongoing Israeli court proceedings for a Debt Arrangement involving the BVI subsidiary's bondholders, where a creditors' meeting date remains unset.

• ·Letter of undertaking entered on August 19, 2025, with Trustee for BVI bondholders.
• ·Trustee applied to Israeli court on December 26, 2025, to convene creditors' meeting; court ordered meeting on February 4, 2026, but date not yet set.
• ·Company's shares of BVI constitute substantially all assets; expects orderly disposal under Debt Arrangement.
• ·Independent directors waived all accrued and future fees to reduce expenses.
• ·No updated estimated net asset value per share to be provided due to financial constraints.

02-03-2026

Generate Biomedicines, Inc. filed an Amended and Restated Certificate of Incorporation on March 02, 2026, restating and integrating its prior certificate from September 2, 2021, originally filed as Flagship VL56, Inc. on August 20, 2018. The document authorizes a total of 510 million shares of capital stock, comprising 500 million shares of common stock and 10 million shares of undesignated preferred stock, both with $0.001 par value. Notable governance changes include prohibiting stockholder actions by written consent, restricting special meetings to board initiation, and implementing a classified board structure with staggered terms post-IPO.

• ·Registered office: Corporation Trust Center, 1209 Orange Street, Wilmington, New Castle County, Delaware 19801.
• ·Registered agent: The Corporation Trust Company.
• ·Directors may be removed only for cause by 2/3 vote of voting power.
• ·Board size fixed exclusively by board resolution; classified into three classes post-IPO with staggered three-year terms.
• ·Vacancies filled solely by board, not stockholders.

02-03-2026

Coca-Cola Europacific Partners plc filed notifications of multiple PDMR transactions on February 19 and 26, 2026, including significant sales by executives Clare Wardle (12,000 Ordinary Shares for $1.26M) and Veronique Vuillod (1,416 Ordinary Shares for $0.15M), which may signal personal profit-taking. However, several executives including CFO Edward Walker, Chief Commercial Officer Stephen Lusk, and others acquired small fractional shares (around 3-4 shares each) under the UK Share Plan at an average of $57.53 and additional shares via RSU vesting or Shareshop, reflecting routine compensation alignments. All transactions occurred on Nasdaq.

• ·All transactions priced around USD $104.94-$105.48 per share for sales; acquisitions include $0.00 volumes for dividend equivalents or vesting.
• ·Company LEI: 549300LTH67W4GWMRF57.
• ·Gareth McGeown transaction on 2026-02-26; all others on 2026-02-19.

02-03-2026

HBT Financial, Inc. completed its merger with CNB Bank Shares, Inc. on March 2, 2026, integrating CNB's $1.8B total assets, $1.3B loans held for investment, and $1.5B deposits (as of Dec 31, 2025) into HBT's $5.1B asset base, $3.5B loans, and $4.4B deposits, expanding its footprint in central Illinois, Chicago MSA, and St. Louis MSA markets. The merger also led to the appointment of James T. Ashworth and Nancy L. Ruyle as new directors to HBT Financial and Heartland Bank boards, effective March 1, 2026, with terms expiring at the 2026 Annual Meeting. No financial performance declines or flat metrics were reported in the announcement.

• ·HBT Financial provides financial products and services through 66 full-service branches in Illinois and eastern Iowa.
• ·Peter Chapman designated as IR contact: HBTIR@hbtbank.com, (309) 664-4556.

02-03-2026

Zymeworks Inc. announced a $250 million non-dilutive royalty-backed note financing from Royalty Pharma, secured by 30% of worldwide tiered royalties on Ziihera from Jazz Pharmaceuticals and BeOne Medicines, while retaining 70% of royalties during repayment and full rights thereafter. Proceeds will strengthen the balance sheet, fund stock repurchases at a perceived discount to intrinsic value, support potential strategic acquisitions, and extend cash runway beyond 2028. Zymeworks retains all milestone payments, including up to $1.5 billion in potential regulatory and commercial milestones.

• ·Repayment to Royalty Pharma from low to mid-single digit tiering royalties up to pre-specified limit, ceasing at 1.65x note by Dec 31, 2033 or 1.925x thereafter.
• ·Jazz royalties: tiered 10% to high teens on global sales (ex-Asia excl. Japan, Australia, NZ) up to $2.0B, 20% above.
• ·BeOne royalties: mid-single to mid-double digits up to $1.0B annual net sales, 19.5% above; holds marketing rights in Asia (ex-Japan), Australia, NZ.
• ·All regulatory and commercial milestones retained by Zymeworks.

02-03-2026

On February 27, 2026, CMS notified Elevance Health, Inc. of its intent to impose intermediate sanctions suspending new Medicare Advantage-Prescription Drug (MA-PD) plan enrollments and certain beneficiary communications, effective March 31, 2026, unless resolved, due to alleged noncompliance with risk adjustment data submission requirements for dates of service prior to April 3, 2023. The sanctions do not impact benefits for current MA-PD members. Elevance Health, which revised its practices in April 2023 following regulatory guidance, is engaging cooperatively with CMS to address the concerns.

• ·Sanctions relate specifically to Medicare Advantage risk adjustment data submission requirements for dates of service prior to April 3, 2023.

02-03-2026

Artificial Intelligence Technology Solutions, Inc. (AITX), through its subsidiary Robotic Assistance Devices, Inc. (RAD), announced a new channel partner placed an immediate first-day order for two RIO™ 360 units, one ROSA™ system, and three SARA™ software licenses, signaling strong confidence in RAD's expanding channel ecosystem and integrated autonomous security solutions. This aligns with RAD's strategy of scaling via committed multi-system deployments in the nearly $50B USD security industry, where RAD offers 35%-80% cost savings over manned guarding. RAD maintains a prospective sales pipeline with over 35 Fortune 500 companies, though no specific order value or revenue impact was disclosed.

• ·RAD has successfully completed SOC 2 Type 2 audit, validating internal controls for customer data protection.
• ·RAD invites security professionals to ISC West 2026 for live demonstrations and meetings.
• ·All RAD technologies, AI-based analytics, and software platforms are developed in-house.

02-03-2026

On February 26, 2026, Tilly’s, Inc. amended its Third Amended and Restated Tilly's 2012 Equity and Incentive Award Plan to increase the maximum aggregate shares of Class A common stock per person per calendar year to 2,500,000 shares. Concurrently, the company canceled and re-granted to President and CEO Nathan Smith time-based options for 900,000 shares and performance-based options for 900,000 shares, originally issued in September 2025, under identical terms including exercise price, vesting, and expiration.

• ·Amendment filed as Exhibit 10.1.
• ·Original options granted to Nathan Smith in September 2025 upon commencement of employment.
• ·Event reported on February 26, 2026; filing signed February 27, 2026.

02-03-2026

On February 27, 2026, ProCap Financial, Inc. completed the acquisition of 450 Bitcoin via the assignment of previously entered put option contracts with FalconX Bravo, Inc., dated January 5 and January 20, 2026. The transaction utilized approximately $35.4 million in net capital sourced from the company's working capital account. No additional financial impacts, declines, or comparative data were disclosed.

• ·Option contracts entered in ordinary course of business
• ·Securities traded on The Nasdaq Stock Market LLC under symbols BRR and BRRWW
• ·Registrant is an emerging growth company

02-03-2026

Humana Inc. reaffirms its FY 2026 guidance of at least $8.89 in GAAP diluted EPS and at least $9.00 in Adjusted (non-GAAP) EPS during senior management investor and analyst meetings scheduled from March 2 to March 31, 2026. This guidance is consistent with the company's press release dated February 11, 2026. Reconciliation includes add-back of $0.15 amortization of identifiable intangibles and $(0.04) cumulative net tax impact.

• ·Investor and analyst meetings scheduled between March 2, 2026 and March 31, 2026
• ·Guidance consistent with press release dated February 11, 2026
• ·FY 2026 ends December 31, 2026
• ·GAAP EPS guidance excludes future value changes to unestimated items; potential changes expected due to strategic initiatives

02-03-2026

Dare Bioscience, Inc. (DARE) filed an 8-K on March 02, 2026, under Items 7.01 (Regulation FD Disclosure) and 9.01 (Financial Statements and Exhibits), attaching Exhibit 99.1. No substantive financial, operational, or performance details are available in the provided filing excerpt.

• ·Filing Type: 8-K
• ·Items Reported: 7.01, 9.01
• ·Subcategory: Regulation FD Disclosure

02-03-2026

Civista Bancshares, Inc. announced that President and CEO Dennis Shaffer will retire effective August 28, 2026, and will be succeeded by Charles 'Chuck' Parcher, current President of Civista Bank, who will assume the roles of President and CEO for both the holding company and bank. Shaffer will remain as Chairman of the Board to ensure a seamless transition after more than 40 years of service. The $4.3B financial holding company operates 44 locations across Ohio, Southeastern Indiana, and Northern Kentucky.

• ·Civista Bank founded in 1884.
• ·Dennis Shaffer has more than 40 years of service in the banking industry.
• ·Common shares traded on NASDAQ Capital Market under symbol 'CIVB'.
• ·Filing date: March 02, 2026.

02-03-2026

Medallion Financial Corp. repaid at maturity the full $31.25M aggregate principal amount of its privately placed notes on February 26, 2026, as disclosed under Regulation FD. No other financial impacts or issues were reported in the filing.

02-03-2026

Peapack-Gladstone Financial Corporation announced its intent to redeem all $100M in aggregate principal amount of its 3.50% Fixed-to-Floating Rate Subordinated Notes due December 22, 2030. The redemption is expected on or about March 2, 2026, at 100% of the principal plus accrued and unpaid interest. The company stated it will remain well capitalized following the redemption.

02-03-2026

News Corporation issued an update to its Appendix 3C buy-back notification for the 2025 Repurchase Program, authorizing repurchases of up to $1B aggregate of Nasdaq-listed Class A (NWSA) and Class B common stock to enhance shareholder value. On February 27, 2026, the company repurchased 86,681 shares for $2.1M, with cumulative purchases to date totaling approximately $82.2M worth of shares out of the $1B authorization. No declines or flat metrics reported; activity reflects steady execution under market conditions.

• ·Highest price paid to date: $27.21 on Feb 2, 2026; on Feb 27: $24.43
• ·Lowest price paid to date: $22.20 on Feb 9, 2026; on Feb 27: $23.97
• ·Broker: Goldman Sachs & Co. LLC
• ·No repurchases of ASX-listed CDIs
• ·Initial buy-back notification date: July 15, 2025

02-03-2026

Pulse Biosciences, Inc. filed an 8-K/A on March 2, 2026, amending its February 27, 2026 8-K to remove two sentences and report the resignation of Kevin P. Danahy, Chief Commercial Officer, effective immediately on February 27, 2026. No reason for the resignation was provided, and no successor or compensatory details were disclosed. The filing has no financial impacts or other material changes.

• ·Registrant headquartered at 601 Brickell Key Drive, Suite 1080, Miami, Florida 33131.
• ·Common stock trades on Nasdaq under ticker PLSE.

02-03-2026

Rallybio Corporation (RLYB) and Candid Therapeutics announced a definitive merger agreement, with Rallybio acquiring Candid; the combined entity will operate as Candid Therapeutics (CDRX) with pro-forma cash of approximately $700M from over $505M concurrent financing, funding operations through 2030 and advancing TCE pipeline including Phase 2 for cizutamig in 2026. However, pre-merger Rallybio equityholders will own only 3.65% of the combined company (Candid 96.35%), representing significant dilution, while Rallybio shareholders receive CVRs linked to legacy asset sales like REV102.

• ·Merger expected to close mid-2026, subject to stockholder approval, HSR waiting period, and other conditions.
• ·CND319 first-in-human studies planned for mid-2026.
• ·Joint conference call held March 2, 2026 at 8:30 AM ET.

02-03-2026

UnitedHealth Group Incorporated appointed Dennis Stankiewicz, age 48, as Chief Accounting Officer effective March 2, 2026, while he continues serving as Corporate Controller since April 17, 2023. Tom Roos, who has been Chief Accounting Officer since August 2015, will transition to Chief Financial Officer of Optum Insight effective the same date. Stankiewicz's compensation includes an annual base salary of $550,000, an initial cash bonus target of 85% of base salary, and severance of one times base salary upon termination without cause.

• ·Dennis Stankiewicz joined UnitedHealth Group in August 2016 as General Auditor and has more than 24 years of professional experience.
• ·Mr. Stankiewicz has not been involved in any transactions requiring disclosure under Item 404(a) of Regulation S-K.
• ·Severance benefits for Stankiewicz conditioned on non-compete during severance period.

02-03-2026

First Financial Corporation (THFF) completed its acquisition of CedarStone Financial, Inc. and CedarStone Bank on March 1, 2026, pursuant to the Merger Agreement dated November 6, 2025. The transaction involved paying $19.12 per share in cash for each share of CedarStone’s common stock, resulting in an aggregate value of approximately $25 million. No financial performance metrics or comparisons were provided in the filing.

• ·Merger Agreement filed as Exhibit 2.1 on November 6, 2025 8-K
• ·CedarStone merged with and into First Financial; CedarStone Bank merged with and into First Financial Bank

02-03-2026

This 8-K filing includes the Annual Report on Form 10-K for the fiscal year ended December 31, 2025, for the entity formerly known as Synovus Financial Corp., filed under Pinnacle Financial Partners, Inc. post-merger. Synovus and Legacy Pinnacle merged into New Pinnacle (f/k/a Steel Newco Inc.) effective January 1, 2026, with the financial statements reflecting Synovus's position as of December 31, 2025. As of June 30, 2025, the aggregate market value of Synovus Common Stock held by non-affiliates was $6.84B at a closing price of $51.75 per share, and 138,893,470 shares were outstanding as of December 31, 2025.

• ·Merger Agreement dated July 24, 2025
• ·Merger effective January 1, 2026 (Effective Time)
• ·Filing date: March 02, 2026
• ·Registrant incorporated in Georgia, EIN 39-3738880
• ·Large accelerated filer and well-known seasoned issuer

02-03-2026

Tyra Biosciences reported Q4 and FY 2025 financial results, with cash, cash equivalents, and marketable securities at $256M, providing runway through at least 2027, alongside launching the 'dabogratinib 3x3' strategy targeting LG-UTUC, IR NMIBC, and ACH with key data readouts for SURF302 by end-1H 2026 and BEACH301 in 2H 2026. However, R&D expenses rose 27% YoY to $28.2M in Q4 and 29% to $102.9M for FY, G&A increased 9% to $8.3M in Q4 and 24% to $29.8M for FY, driving net losses wider to $33.8M in Q4 (up 32%) and $119.9M for FY (up 39%). Cash position declined from $341.5M at end-2024 amid ongoing clinical investments.

• ·Exited metastatic bladder cancer (SURF301 no longer recruiting)
• ·Appointed Bhavesh Ashar as COO and Heather Faulds as Chief Regulatory Officer in Q4 2025
• ·SURF303 first patient dosing anticipated 2026
• ·BEACH301 cleared two of four dose levels with no safety events
• ·FDA Orphan Drug and Rare Pediatric Disease Designations for dabogratinib in achondroplasia

02-03-2026

Newbridge Acquisition Limited, a blank check company, entered into a non-binding Memorandum of Understanding (MOU) with Starcoin Group Limited (formerly Innovative Pharmaceutical Biotech Limited, HKEX: 399) on February 27, 2026, to explore a potential de-SPAC transaction involving Starcoin and/or its assets or businesses. The MOU requires due diligence and definitive agreements to proceed and terminates 180 days after signing unless extended. No transaction is guaranteed, and shareholders are advised to exercise caution when dealing in the Company's securities.

• ·MOU termination: earlier of definitive agreements or 180 days after February 27, 2026
• ·Company securities: NBRGU (Units), NBRG (Class A Ordinary Shares), NBRGR (Rights) listed on Nasdaq
• ·Starcoin listed on The Stock Exchange of Hong Kong Limited (stock code 399)

02-03-2026

Lifeward Ltd. (LFWD) completed a 1-for-12 reverse share split effective February 24, 2026, reducing outstanding Ordinary Shares from 18,339,098 to approximately 1,528,098 to comply with Nasdaq Capital Market's $1.00 minimum bid price listing requirement. The company simultaneously adopted its Eighth Amended and Restated Articles of Association, increasing authorized Ordinary Shares from 75,000,000 to 100,000,000. Outstanding warrants and stock options were proportionately adjusted.

• ·Shareholder approval at Extraordinary General Meeting on January 6, 2026.
• ·Finance Committee approved 1-for-12 ratio on January 30, 2026, and amendments on February 16, 2026.
• ·Trading on split-adjusted basis began February 24, 2026, under symbol LFWD with new CUSIP M8216Q309.
• ·No fractional shares issued; fractions rounded down.

02-03-2026

Voya Financial, Inc. completed a $400M registered public offering of 5.050% Senior Notes due 2036 on March 2, 2026, fully guaranteed by its wholly-owned subsidiary Voya Holdings Inc., yielding net proceeds of approximately $395.2M after commissions and expenses. Proceeds are intended for general corporate purposes, potentially including repayment of the $447M outstanding 3.65% Senior Notes due June 15, 2026. No declines or flat metrics reported in this debt issuance event.

• ·Notes issued under Base Indenture dated July 13, 2012, supplemented by Tenth Supplemental Indenture dated March 2, 2026.
• ·Interest payable semi-annually on March 2 and September 2, beginning September 2, 2026.
• ·Voya may redeem Notes in whole or in part at any time at prices specified in Supplemental Indenture.
• ·Underwriting Agreement dated February 23, 2026, with Citigroup Global Markets Inc., BofA Securities, Inc., and Wells Fargo Securities, LLC as representatives.

02-03-2026

Stewart Information Services Corporation (STC) announced that its Board of Directors declared a cash dividend of $0.525 per share on its common stock for the first quarter 2026. The dividend is payable on March 31, 2026, to common stockholders of record on March 16, 2026. This declaration was disclosed via press release on March 2, 2026, under Regulation FD.

• ·Common stock trades on NYSE under ticker STC
• ·Registrant incorporated in Delaware, principal office at 1360 Post Oak Blvd, Suite 100, Houston, Texas 77056

02-03-2026

Tidewater Inc. reported full-year 2025 revenue of $1.35B, up 0.5% YoY from $1.35B, with average day rates rising 6.1% to $22,573, Adjusted EBITDA of $598.1M, net income of $334.7M boosted by a $201.5M non-cash deferred tax benefit from vessel realignment, and free cash flow of $426M. However, Q4 2025 revenue declined 2.4% YoY to $336.8M from $345.1M, with day rates down 0.9% to $22,044. The company updated 2026 guidance to $1.43-1.48B revenue and 49-51% gross margins pro forma for the Wilson Sons Ultratug acquisition, and maintains a $500M share repurchase authorization.

• ·EPS full-year 2025: $6.64 (diluted), Q4 2025: $4.41 vs. full-year 2024: $3.40, Q4 2024: $0.70
• ·In-the-money warrants as of Dec 31, 2025: 21,400 New Creditor Warrants (strike $0.001), 53,555 GulfMark Creditor Warrants (strike $0.01)
• ·Conference call scheduled for March 3, 2026 at 8:00 a.m. Central Time

02-03-2026

KeyCorp announced that Chief Information Officer Amy G. Brady informed the company of her resignation effective March 2, 2026, due to personal health considerations, with a transition period as a non-executive employee through May 31, 2026. Under the Transition Letter dated March 2, 2026, Ms. Brady will receive one year of salary continuation and benefits post-termination, eligibility for 2026 incentive compensation, and continued vesting in her Capital and Earnings Improvement Award granted December 30, 2024, subject to a release of claims. The departure is structured for an orderly transition with no quantified financial impacts disclosed.

• ·Event reported date: February 24, 2026
• ·Transition Letter filed as Exhibit 10.1

02-03-2026

Klotho Neurosciences, Inc. closed a private placement financing on March 2, 2026, issuing 34,551,939 shares of common stock and warrants to purchase an additional 34,551,939 shares to accredited investors, generating approximately $7.75 million in gross proceeds. The transaction relied on exemptions under Section 4(a)(2) of the Securities Act and Rule 506 of Regulation D, with no general solicitation.

• ·Securities Purchase Agreement dated February 19, 2026; details in prior 8-K filed February 24, 2026.
• ·Issuance exempt under Section 4(a)(2) of Securities Act and Rule 506 of Regulation D.
• ·Purchasers are accredited investors acquiring for investment, not distribution.
• ·Company is an emerging growth company.

02-03-2026

Proficient Auto Logistics reported preliminary total revenue of approximately $55M for January and February 2026, roughly 4% below the comparable period in 2025, due to extended plant shutdowns, weak SAAR, severe winter weather, and slower recovery in transportation pipelines, with February revenue also lower YoY and $6-8M short of expectations. The company announced a $15M share repurchase program as a vote of confidence in its financial health and balance sheet strength. While full Q1 revenue will be below prior expectations with a sequential increase in adjusted operating ratio, March revenue and profitability expectations remain intact amid seasonal strengthening.

• ·Conference attendance by Rick O’Dell, Amy Rice, and Brad Wright on March 4, 2026, with materials posted on proficientautologistics.com under Investor Relations.
• ·Share repurchases to be funded from cash on hand, borrowings under revolving credit facility, and/or future cash flows; no time limit set.
• ·Run rates for volume and revenue returned to expected levels absent late February Northeast weather impacts.

02-03-2026

Intuitive Surgical, Inc. completed its acquisition of the da Vinci and Ion distribution business operated by ab medica, Abex, Excelencia Robótica, and their affiliates on March 1, 2026. The company issued a press release on March 2, 2026, announcing the transaction, with the press release furnished as Exhibit 99.1. No financial terms, performance metrics, or other quantitative details were disclosed in the filing.

• ·Acquisition closed on March 1, 2026; press release dated March 2, 2026